SEP 2 3 2002

Approved for use through W/3 14 be 2.9 into both 2001.

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/PT	0		Complete If Known		
000	311010 101 101111 1 1 1 1 1 1 1			Application Number	09/830,810	
١N	IFORMATIO	N DI	SCLOSURE	Filing Date	October 28, 1999	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Martin M. Matzuk	
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1653	
	(use as many s	sheets as	necessary)	Examiner Name	J. Olsen	
Sheet	1	of	4	Attorney Docket Number	HO-P01925US1	

_				U.S. PA	TENT DOCUMENTS	
Examiner		Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevant
Init	Initials*	No.1	Number-Kind Code <sup>2</sup> (# known)	MM-DD-TTTT	of Cited Document	Figures Appear
Z	3	AA	5801016-	09-01-1998	Morioka et al.	<u> </u>
*	\$ <del>\</del>	AB	5547854-	08-20-1996	Donahoe et al.	
	<b>(</b> 5)	AC	5563059-	10-08-1996	Alak et al.	
		AD	5661126-	08-26-1997	Donahoe et al.	

	FORE	GN PATENT :	DOCUMENTS		
Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (If known)	MARON	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7°
ВА	-WO98/40483-	100	1.		
	No.1	Cite No.1  Foreign Patent Occument  Country Code3-Number4-Kind Code1(# known)	Cite Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (# known)  A -WO98/40483-  Publication Date MM-DD-YYYY  09-17-1998	Cite No. 1 Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) MM-DD-YYYY Applicant of Cited Document	Foreign Patent Document Cite No.  Country Code <sup>3</sup> Number Aind Code <sup>5</sup> (If known)  Publication Date MM-DD-YYYY Applicant of Cited Document Passages or Relevant Figures Appear  NA -WO98/40483-  D9-17-1998 Human Genome Sciences,

$\sim$	
Examiner	Date LAG 01
	Considered T 7 114
Signature	- Considered 17 1 C

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (options!). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>8</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

TECH CENTER 1600/2900
PTO/SB/06B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB control number.

Cub	stitute for form 1449B	/PTO	*	Complete if Kn wn		
300	SUIDIO IOI IOIIII 14400	<i>i</i> - 10		Application Number	09/830,810	
IN	IFORMATI:	ON DIS	SCLOSURE	Filing Date	October 28, 1999	
STATEMENT BY APPLICANT				First Named Inventor	Martin M. Matzuk	
Ŭ	17(12)(12)			Group Art Unit	1653	
-	(use as many sheets as necessary)			Examiner Name	J. Olsen	
heet	2	of	4	Attorney Docket Number	HO-P01925US1	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
1	CA	Elvin, Julia A., et al.; Paracrine Actions of Growth Differentiatin Factor-9 in the Mammalian Oyany Molecular Endocrinology, Vol. 13, No. 6, 1999	
<i>X</i> ) <i>X</i> )	СВ	Elvin, Julia A., et al.; Molecular Characterization of the Follicle Defects in the Growth Differentiation Factor 9-Deficient Ovary: Molecular Endocrinology, Vol. 13, No. 6; 1999	
10	СС	Matzuk, Martin M., et al.; Transgenic Models to Study the Roles of Inhibins and Activins in Reproduction, Oncogenesis, and Development; Recent Progess in Hormone Research, Vol. 51	
1	CD	Ohsumi, Keita, et al.; Characterization of the Ooplasmic Factor Inducing Decondensation of and Protamine Removal from Toad Sperm Nuclei: Involvement of Nucleoplasmin;	
A)	CE	Philpott, Anna, et al.; Nucleoplasmin Remodels Sperm Chromatin in Xenopus Egg Extracts;	
A)	CF	Matzuk, Martin M., et al.; Different phenotypes for mice deficient in either activins or activing recentor type II: Nature: Vol. 374: 1995	
10	CG	Dong, Jinwen, et al.; Growth differentiation factor-9 is required during early ovarian	
A	СН	McGrath, Sharon A., et al.; Oocyte-Specific Expression of Growth/Differentiation Factor-9;	
A)	CI	Kumar, T. Rajendra, et al.; Follicle stimulating hormone is required for ovarian follicle	
NC	CU	Perreault, Sally D.; Chromatin remodeling in mammalian zygotes; Mutation Research; vol.	
W	СК	Krohne, Georg, et al.; Immunological identification and localization of the predominant nuclear protein of the amphibian occure nucleus: Proc. Natl. Acad. Sci. USA; Vol. 77; 1980	
1	CL	Matzuk, Martin M., et al.; a Inhibin is a tumour-suppressor gene with gonadal specificity in	
	СМ	Elvin, Julia A., et al.; Growth differentiation factor-9 stimulates progesterone synthesis in	
10	CN	MacArthur, Craig A., et al.; Npm3: A Novel, Widely Expressed Gene Encoding a Protein Related to the Molecular Chaperones Nucleoplasmin and Nucleophosmin; Genomics; Vol. 42;	
<b>A</b>	со	Mills, A. D., et al.; An Acidic Protein Which Assembles Nucleosomes in Vitro is the Most	
6	СР	Dingwall, Colin, et al.; Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals; The EMBO Journal; 1987	
P	ca	McLay, David W., et al.; The Ability to Organize Sperm DNA into Functional Chromatin Is	
1	CR	Carabatsos, Mary Jo, et al.; Characterization of Oocyte and Follicle Development in Growth Differentiation Factor-9-Devicient Mice: Developmental Biology; Vol. 204; 1998	
A	cs	Philipott, Anna, et al.; Sperm Decondensatino in Xenopus Egg Cytoplasm is Mediated by	<u> </u>
10	СТ	Burglin, Thomas R., et al.; Cloning of nucleoplasmin from Xenopus laevis oocytes and analysis of its developmental expression; Genes & Development; Vol. 1; 1987	

Date Considered Examiner Signature

Sheet

3

HO-P01925US1

Approved for use through TPE/PAPP AND PERIODE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO 09/830,810 Application Number INFORMATION DISCLOSURE October 28, 1999 Filing Date STATEMENT BY APPLICANT First Named Inventor Martin M. Matzuk Group Art Unit 1653 (use as many sheets as necessary) J. Olsen Examiner Name

Attorney Docket Number

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002\_OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numbers.

Complete If Known Substitute for form 1449A/PTO 09/830,810 Application Number INFORMATION DISCLOSURE October 28, 1999 Filing Date Martin M. Matzuk First Named Inventor STATEMENT BY APPLICANT 1653 Art Unit (use as many sheets as necessary) Examiner Name Steven Post Attorney Docket Number HO-P01925US1 of 3 Sheet

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°	
<i>R</i> 3	ВА	WO-00/24755-A1	05-04-2000	Baylor College of Medicine		<u>L</u>	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Exeminer Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	Τ2
40	CA	Wu, X., et al.; Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to- embryo transition; Nat Genet. 33(2):187 - 191, February 2003	
10	СВ	Matzuk, M.M., et al.; Genetic dissection of mammalian fertility pathways; Nat Cell Biol. Suppl 4:S41 - 49, October 2002	
, 10	CC	Varani, S., et al.; Phenotypic effects of knockout of oocyte-specific genes; Ernst Schering Res Found Workshop (41):63 - 79, 2002	
10	CD	Matzuk, M. M., et al.; Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science 296 (5576):2178 - 2180; June 21, 2002	
(1)	CE	Rajkovic, A., et al.; Functional analysis of oocyte-expressed genes using transgenic models.  Mol Cell Endocrinol. 187(1-2):5 - 9, February 22, 2002	
10	CF	Yan, C., et al.; Oosp1 encodes a novel mouse oocytesecreted protein; Genesis 31(3):105 - 110. November 2001	
W	CG	Lau, A., et al.; Transgenic models in the study of reproduction; Gravit Space Biol Bull. 12(2):75 - 82, May 1999	<u> </u>
10	СН	Elvin, J.A., et al.; Oocyte-expressed TGF-beta superfamily members in female fertility; Mol Cell Endocrinol 159(1-2):1 - 5, January 25, 2000	
40	CI	The Sanger Centre, et al.; Toward a Complete Human Genome Sequence; Genome Research 8:1097 – 1108, 1998	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 6	\		
Examiner Signature		Date Considered	4-9-04

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.